2026
conference-abstract
OpenAlex
Vadim S. Koshkin, Christine Abraham Jaillon, Nataliya Mar, Denis Maillet et autres
4562 Background: Approximately 50-80% of patients (pts) with la/mUC have tumors with HER2 protein expression. As HER2-directed therapies enter development, a robust understanding of HER2 prevalence and real-world outcomes with standard-of-care (SOC) therapies across HER2 expression subgroups is needed. SGNDV-003 (NCT05902494) is …
us, fr, at, de
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Thomas B. Powles, Enrique Grande, Nimira S. Alimohamed, Niara Oliveira et autres
INTRODUCTION: Platinum-based chemotherapy for the treatment of locally advanced or metastatic urothelial carcinoma (la/mUC), has been the first-line standard of care for many decades. Enfortumab vedotin, an antibody-drug conjugate, combined with pembrolizumab, a programmed death 1 (PD-1) inhibitor, recently demonstrated improved efficacy …
gb, us, es, ca, au, sg, fr, it
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Mazyar S. Shadman, Beenish S. Manzoor, Kavita Sail, Hande H. Tuncer et autres
INTRODUCTION: This study assessed treatment discontinuation patterns and reasons among chronic lymphocytic leukemia (CLL) patients initiating first-line (1L) and second-line (2L) treatments in real-world settings. MATERIALS AND METHODS: Using deidentified electronic medical records from the CLL Collaborative Study of Real-World Evidence, premature …
us, gb, de, ca
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Jeffrey P. Sharman, Juliana M.L. Biondo, Michelle Boyer, Kirsten Fischer et autres
We reviewed the literature (January 2010-June 2021) on the effectiveness of debulking strategies before venetoclax initiation in patients with chronic lymphocytic leukemia to reduce tumor burden, downgrade tumor lysis syndrome (TLS) risk, and avoid hospitalization. Low TLS incidence and reduced TLS risk …
us, gb, de, nl, ch
(code pays fourni par la source)
2021
article
OpenAlex
Matthew Steven Davids, Mazyar S. Shadman, Sameer Ashok Parikh, Chaitra Shankar Ujjani et autres
The efficacy of venetoclax in chronic lymphocytic leukemia (CLL) is well established.1-3 Venetoclax is approved with a 5-week dose ramp-up schedule to mitigate risk of tumor lysis syndrome (TLS); dosing is increased weekly according to a schedule of 20 mg, 50 mg, …
us
(code pays fourni par la source)
2021
conference-abstract
OpenAlex
Ian W. Flinn, David Jacob Andorsky, Jason M. Melear, Sudhir Manda et autres
Abstract Background: Venetoclax (VEN), an oral B-cell lymphoma 2 inhibitor, is approved for use in adult patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). As a targeted and highly active antitumor agent, VEN induces rapid and profound tumor reduction. Inpatient …
us
(code pays fourni par la source)
2020
article
OpenAlex
Matthew Steven Davids, Mazyar S. Shadman, Sameer Ashok Parikh, Chaitra Shankar Ujjani et autres
Background: The rapid reduction in tumor burden by the oral B-cell lymphoma-2 inhibitor venetoclax (Ven) poses a risk of tumor lysis syndrome (TLS) for patients (pts) with chronic lymphocytic leukemia (CLL). The approved 5-week Ven dose ramp-up, along with prophylaxis and monitoring, …
us
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Jane Pendergast, Chi H. Lin, Dingfeng Jiang, Robert Benedict Wallace et autres
Pre-operative (pre-op) chemoradiation therapy (CRT) improves local control and reduces toxicity more than post-operative (post-op) CRT for the treatment of stages II/III rectal cancer, but studies suggest many patients still receive post-op CRT. We examined patient beliefs, and clinical and provider characteristics …
us
(code pays fourni par la source)
2020
conference-abstract
OpenAlex
Jeff Porter Sharman, David Jacob Andorsky, Jason M. Melear, Sudhir Manda et autres
us
(code pays fourni par la source)
2019
conference-abstract
OpenAlex
Jeff Porter Sharman, David Jacob Andorsky, Jason M. Melear, Sudhir Manda et autres
BACKGROUND: Venetoclax is an effective oral agent for frontline treatment of patients with chronic lymphocytic leukemia (CLL). Due to the rapid induction of cell death caused by the targeted activity of venetoclax, some patients require inpatient monitoring for tumor lysis syndrome (TLS) …
us
(code pays fourni par la source)
2019
book-chapter
OpenAlex
Dingfeng Jiang, Kun Chen, Saurabh Mukhopadhyay, Nareen Katta et autres
us
(code pays fourni par la source)
2017
article
OpenAlex
Tatyana A. Kapustyan, Holger Keim, Brian L. Meissner, Jacqueline Nielsen et autres
Abstract Background: CLL is the most common type of leukemia in adults in the US. Traditionally, chemotherapy (CT) and chemoimmunotherapy (CIT) have been the treatment mainstay, with new oral-targeted options recently becoming available. CLL patients (pts) who relapse and/or are refractory to …
us
(code pays fourni par la source)